Prostate cancer stem cells: Are they androgen-responsive?

Molecular and Cellular Endocrinology

Volumn 360, Issue 1-2, 2012, Pages 14-24

  Oldridge, Emma E ^a   Pellacani, Davide ^a   Collins, Anne T ^a   Maitland, Norman J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Androgen; Differentiation; Prostate; Stem cells

Indexed keywords

ABC TRANSPORTER; ANDROGEN; ANDROGEN RECEPTOR; CYTOKERATIN; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; NOTCH RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; BASAL CELL; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL STRUCTURE; CELL SURVIVAL; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; EPIGENETICS; EXPERIMENTAL MODEL; GENE EXPRESSION REGULATION; HOMEOSTASIS; HORMONE ACTION; HUMAN; INTRACELLULAR SIGNALING; LUMINAL STEM CELL; METASTASIS POTENTIAL; MOLECULAR MECHANICS; NONHUMAN; ORGANOGENESIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGENY; PROSTATE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; REVIEW; SECRETORY CELL; STEM CELL; TRANSCRIPTION INITIATION; TREATMENT RESPONSE;

ANDROGENS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84864024116     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.008     Document Type: Review

References (171)

1. Abate-Shen C., Shen M.M. Molecular genetics of prostate cancer. Genes and Development 2000, 14:2410-2434.
2. Abrahamsson P.A., Falkmer S., Falt K., Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an " endocrine marker". Pathology, Research and Practice 1989, 185:373-380.
3. Ahlgren G., Pedersen K., Lundberg S., Aus G., Hugosson J., Abrahamsson P.A. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000, 42:274-279.
4. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:3983-3988.
5. Alam T.N., O'Hare M.J., Laczko I., Freeman A., Al-Beidh F., Masters J.R., Hudson D.L. Differential expression of CD44 during human prostate epithelial cell differentiation. Journal of Histochemistry and Cytochemistry 2004, 52:1083-1090.
6. Ansel K.M., Lee D.U., Rao A. An epigenetic view of helper T cell differentiation. Nature Immunology 2003, 4:616-623.
7. Asamoto M., Hokaiwado N., Cho Y.M., Takahashi S., Ikeda Y., Imaida K., Shirai T. Prostate carcinomas developing in transgenic rats with SV-40 T-antigen expression under probasin promoter control are strictly androgen dependent. Cancer Research 2001, 61:4693-4700.
8. Aumuller G. Morphologic and endocrine aspects of prostatic function. Prostate 1983, 4:195-214.
9. Aumuller G. Postnatal development of the prostate. Bulletin de l'Association des Anatomistes (Nancy) 1991, 75:39-42.
10. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
11. Beildeck M.E., Gelmann E.P., Byers S.W. Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway. Experimental Cell Research 2010, 316:1763-1772.
12. Berman D.M., Desai N., Wang X., Karhadkar S.S., Reynon M., Abate-Shen C., Beachy P.A., Shen M.M. Roles for Hedgehog signaling in androgen production and prostate ductal morphogenesis. Developmental Biology 2004, 267:387-398.
13. Berry P.A., Maitland N.J., Collins A.T. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Molecular and Cellular Endocrinology 2008, 288:30-37.
14. Birnie R., Bryce S.D., Roome C., Dussupt V., Droop A., Lang S.H., Berry P.A., Hyde C.F., Lewis J.L., Stower M.J., Maitland N.J., Collins A.T. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biology 2008, 9:R83.
15. Bohrer M.H., Schmoll J. Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas. Verhandlungen der Deutschen Gesellschaft fur Pathologie 1993, 77:107-110.
16. Bonkhoff H., Remberger K. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Archiv: An International Journal of Pathology, Anatomy and Histopathology 1993, 422:35-38.
17. Bonkhoff H., Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996, 28:98-106.
18. Bonkhoff H., Stein U., Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994, 24:114-118.
19. Bonkhoff H., Stein U., Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Human Pathology 1995, 26:167-170.
20. Bonkhoff H., Wernert N., Dhom G., Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991, 19:91-98.
21. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 1997, 3:730-737.
22. Brandes D. The fine structure and histochemistry of prostatic glands in relation to sex hormones. International Review of Cytology 1966, 20:207-276.
23. Brown M.D., Gilmore P.E., Hart C.A., Samuel J.D., Ramani V.A., George N.J., Clarke N.W. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007, 67:1384-1396.
24. Bruce W.R., Van Der Gaag H. A Quantitative Assay for the Number of Murine Lymphoma Cells Capable of Proliferation in Vivo. Nature 1963, 199:79-80.
25. Brunschwig C.S. Quantitative studies of autotransplantation of human cancer. Cancer 1961, 14:461-563.
26. Bui M., Reiter R.E. Stem cell genes in androgen-independent prostate cancer. Cancer and Metastasis Reviews 1998, 17:391-399.
27. Burger P.E., Gupta R., Xiong X., Ontiveros C.S., Salm S.N., Moscatelli D., Wilson E.L. High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009, 27:2220-2228.
28. Burger P.E., Xiong X., Coetzee S., Salm S.N., Moscatelli D., Goto K., Wilson E.L. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:7180-7185.
29. Cerveira N., Ribeiro F.R., Peixoto A., Costa V., Henrique R., Jeronimo C., Teixeira M.R. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006, 8:826-832.
30. Chaudhary P.M., Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66:85-94.
31. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004, 10:33-39.
32. Chiou S.H., Kao C.L., Chen Y.W., Chien C.S., Hung S.C., Lo J.F., Chen Y.J., Ku H.H., Hsu M.T., Wong T.T. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS ONE 2008, 3:e2090.
33. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research 2005, 65:10946-10951.
34. Collins A.T., Habib F.K., Maitland N.J., Neal D.E. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. Journal of Cell Science 2001, 114:3865-3872.
35. Craft N., Chhor C., Tran C., Belldegrun A., DeKernion J., Witte O.N., Said J., Reiter R.E., Sawyers C.L. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Research 1999, 59:5030-5036.
36. Cunha G.R., Ricke W., Thomson A., Marker P.C., Risbridger G., Hayward S.W., Wang Y.Z., Donjacour A.A., Kurita T. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. Journal of Steroid Biochemistry and Molecular Biology 2004, 92:221-236.
37. De Marzo A.M., Bradshaw C., Sauvageot J., Epstein J.I., Miller G.J. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998, 34:162-168.
38. De Marzo A.M., Meeker A.K., Epstein J.I., Coffey D.S. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. American Journal of Pathology 1998, 153:911-919.
39. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nature Reviews Cancer 2005, 5:275-284.
40. Demichelis F., Rubin M.A. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. Journal of Clinical Pathology 2007, 60:1185-1186.
41. Denmeade S.R., Isaacs J.T. A history of prostate cancer treatment. Nature Reviews Cancer 2002, 2:389-396.
42. Dilworth S.M. Cell alterations induced by the large T-antigens of SV-40 and polyoma virus. Seminars in Cancer Biology 1990, 1:407-414.
43. Edwards J., Krishna N.S., Grigor K.M., Bartlett J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. British Journal of Cancer 2003, 89:552-556.
44. El-Alfy M., Pelletier G., Hermo L.S., Labrie F. Unique features of the basal cells of human prostate epithelium. Microscopy Research and Technique 2000, 51:436-446.
45. English H.F., Santen R.J., Isaacs J.T. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987, 11:229-242.
46. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation 2008, 15:504-514.
47. Evans G.S., Chandler J.A. Cell proliferation studies in the rat prostate: II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation. Prostate 1987, 11:339-351.
48. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. Journal of Clinical Oncology 2008, 26:2839-2845.
49. Fabian A., Barok M., Vereb G., Szollosi J. Die hard: are cancer stem cells the Bruce Willises of tumor biology?. Cytometry A 2009, 75:67-74.
50. Fan G., Martinowich K., Chin M.H., He F., Fouse S.D., Hutnick L., Hattori D., Ge W., Shen Y., Wu H., ten Hoeve J., Shuai K., Sun Y.E. DNA methylation controls the timing of astrogliogenesis through regulation of JAK-STAT signaling. Development 2005, 132:3345-3356.
51. Frame F.M., Hager S., Pellacani D., Stower M.J., Walker H.F., Burns J.E., Collins A.T., Maitland N.J. Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells. Experimental Cell Research 2010, 316:3161-3171.
52. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. Journal of Clinical Investigation 2010, 120:41-50.
53. Garraway I.P., Sun W., Tran C.P., Perner S., Zhang B., Goldstein A.S., Hahm S.A., Haider M., Head C.S., Reiter R.E., Rubin M.A., Witte O.N. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate 2010, 70:491-501.
54. Gelmann E.P. Molecular biology of the androgen receptor. Journal of Clinical Oncology 2002, 20:3001-3015.
55. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., Angelopoulou R., Rosen J.M., Greenberg N.M. Metastatic prostate cancer in a transgenic mouse. Cancer Research 1996, 56:4096-4102.
56. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemotheraphy Reports 1966, 50:125-128.
57. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell-of-origin for human prostate cancer. Science 2010, 329:568-571.
58. Goldstein A.S., Lawson D.A., Cheng D., Sun W., Garraway I.P., Witte O.N. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:20882-20887.
59. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., Rosen J.M. Prostate cancer in a transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:3439-3443.
60. Grisanzio C., Signoretti S. P63 in prostate biology and pathology. Journal of Cellular Biochemistry 2008, 103:1354-1368.
61. Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Kong X., Melamed J., Tepper C.G., Kung H.J., Brodie A.M., Edwards J., Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 2009, 69:2305-2313.
62. Hall J.A., Maitland N.J., Stower M., Lang S.H. Primary prostate stromal cells modulate the morphology and migration of primary prostate epithelial cells in type 1 collagen gels. Cancer Research 2002, 62:58-62.
63. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463.
64. Han G., Buchanan G., Ittmann M., Harris J.M., Yu X., Demayo F.J., Tilley W., Greenberg N.M. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:1151-1156.
65. Harrison D.E., Lerner C.P. Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood 1991, 78:1237-1240.
66. Hayward S.W., Dahiya R., Cunha G.R., Bartek J., Deshpande N., Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cellular and Developmental Biology - Animal 1995, 31:14-24.
67. Hayward S.W., Wang Y., Cao M., Hom Y.K., Zhang B., Grossfeld G.D., Sudilovsky D., Cunha G.R. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Research 2001, 61:8135-8142.
68. Hsieh J., Gage F.H. Epigenetic control of neural stem cell fate. Current Opinion in Genetics and Development 2004, 14:461-469.
69. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., Han M., Partin A.W., Vessella R.L., Isaacs W.B., Bova G.S., Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 2009, 69:16-22.
70. Huang J., Yao J.L., di Sant'Agnese P.A., Yang Q., Bourne P.A., Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006, 66:1399-1406.
71. Hudson D.L., Guy A.T., Fry P., O'Hare M.J., Watt F.M., Masters J.R. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. Journal of Histochemistry and Cytochemistry 2001, 49:271-278.
72. Huggins C., Stevens R.E., Hodges C.V. Studies On Prostatic Cancer II. The effects Of castration on advanced carcinoma of the prostate gland. Archives of Surgery 1941, 43:209-223.
73. Hurt E.M., Kawasaki B.T., Klarmann G.J., Thomas S.B., Farrar W.L. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. British Journal of Cancer 2008, 98:756-765.
74. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate. Supplement 1989, 2:33-50.
75. Jiborn T., Bjartell A., Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998, 51:585-589.
76. Kallakury B.V., Yang F., Figge J., Smith K.E., Kausik S.J., Tacy N.J., Fisher H.A., Kaufman R., Figge H., Ross J.S. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer 1996, 78:1461-1469.
77. Karhadkar S.S., Bova G.S., Abdallah N., Dhara S., Gardner D., Maitra A., Isaacs J.T., Berman D.M., Beachy P.A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707-712.
78. Kasper S. Stem cells: The root of prostate cancer?. Journal of Cellular Physiology 2008, 216:332-336.
79. Kellokumpu-Lehtinen P., Santti R., Pelliniemi L.J. Early cytodifferentiation of human prostatic urethra and Leydig cells. Anatomical Record 1979, 194:429-443.
80. Kellokumpu-Lehtinen P., Santti R.S., Pelliniemi L.J. Development of human fetal prostate in culture. Urological Research 1981, 9:89-98.
81. Kelly K., Yin J.J. Prostate cancer and metastasis initiating stem cells. Cell Research 2008, 18:528-537.
82. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
83. Kim M., Turnquist H., Jackson J., Sgagias M., Yan Y., Gong M., Dean M., Sharp J.G., Cowan K. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clinical Cancer Research 2002, 8:22-28.
84. Kinbara H., Cunha G.R., Boutin E., Hayashi N., Kawamura J. Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Prostate 1996, 29:107-116.
85. Korsten H., Ziel-van der Made A., Ma X., van der Kwast T., Trapman J. Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS ONE 2009, 4:e5662.
86. Lang S.H., Frame F.M., Collins A.T. Prostate cancer stem cells. Journal of Pathology 2009, 217:299-306.
87. Lang S.H., Stark M., Collins A., Paul A.B., Stower M.J., Maitland N.J. Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth and Differentiation 2001, 12:631-640.
88. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
89. Lawson D.A., Xin L., Lukacs R.U., Cheng D., Witte O.N. Isolation and functional characterization of murine prostate stem cells. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:181-186.
90. Lawson D.A., Zong Y., Memarzadeh S., Xin L., Huang J., Witte O.N. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:2610-2615.
91. Lee J.T., Herlyn M. Old disease, new culprit: tumor stem cells in cancer. Journal of Cellular Physiology 2007, 213:603-609.
92. Leong K.G., Gao W.Q. The Notch pathway in prostate development and cancer. Differentiation 2008, 76:699-716.
93. Leong K.G., Wang B.E., Johnson L., Gao W.Q. Generation of a prostate from a single adult stem cell. Nature 2008, 456:804-808.
94. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Research 2007, 67:1030-1037.
95. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
96. Li P., Yu X., Ge K., Melamed J., Roeder R.G., Wang Z. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. American Journal of Pathology 2002, 161:1467-1474.
97. Liao C.P., Adisetiyo H., Liang M., Roy-Burman P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Research 2010, 70:7294-7303.
98. Liao C.P., Zhong C., Saribekyan G., Bading J., Park R., Conti P.S., Moats R., Berns A., Shi W., Zhou Z., Nikitin A.Y., Roy-Burman P. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Research 2007, 67:7525-7533.
99. Liu A.Y., True L.D., LaTray L., Nelson P.S., Ellis W.J., Vessella R.L., Lange P.H., Hood L., van den Engh G. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:10705-10710.
100. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular Cancer 2006, 5:67.
101. Liu Z., Turkoz A., Jackson E.N., Corbo J.C., Engelbach J.A., Garbow J.R., Piwnica-Worms D.R., Kopan R. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. Journal of Clinical Investigation 2011, 121:800-808.
102. Lou W., Krill D., Dhir R., Becich M.J., Dong J.T., Frierson H.F., Isaacs W.B., Isaacs J.T., Gao A.C. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Research 1999, 59:2329-2331.
103. Lu W., Tinsley H.N., Keeton A., Qu Z., Piazza G.A., Li Y. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. European Journal of Pharmacology 2009, 602:8-14.
104. Ma S., Chan K.W., Hu L., Lee T.K., Wo J.Y., Ng I.O., Zheng B.J., Guan X.Y. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132:2542-2556.
105. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
106. Ma X., Ziel-van der Made A.C., Autar B., van der Korput H.A., Vermeij M., van Duijn P., Cleutjens K.B., de Krijger R., Krimpenfort P., Berns A., van der Kwast T.H., Trapman J. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Research 2005, 65:5730-5739.
107. Macintosh C.A., Stower M., Reid N., Maitland N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Research 1998, 58:23-28.
108. Maitland N.J., Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU International 2005, 96:1219-1223.
109. Maitland N.J., Frame F.M., Polson E.S., Lewis J.L., Collins A.T. Prostate Cancer Stem Cells: Do They Have a Basal or Luminal Phenotype?. Hormones and Cancer 2011, 2:47-61.
110. Mao P., Angrist A. The fine structure of the basal cell of human prostate. Laboratory Investigation 1966, 15:1768-1782.
111. Meeker A.K., Hicks J.L., Iacobuzio-Donahue C.A., Montgomery E.A., Westra W.H., Chan T.Y., Ronnett B.M., De Marzo A.M. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clinical Cancer Research 2004, 10:3317-3326.
112. Meeker A.K., Hicks J.L., Platz E.A., March G.E., Bennett C.J., Delannoy M.J., De Marzo A.M. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Research 2002, 62:6405-6409.
113. Miller G.J., Cygan J.M. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. Journal of Urology 1994, 152:1709-1713.
114. Miller S.J., Lavker R.M., Sun T.-T. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochimica et Biophysica Acta 2005, 1756:25-52.
115. Moore K.A., Lemischka I.R. Stem cells and their niches. Science 2006, 311:1880-1885.
116. Moskaluk C.A., Duray P.H., Cowan K.H., Linehan M., Merino M.J. Immunohistochemical expression of pi-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate. Cancer 1997, 79:1595-1599.
117. Nagle R.B., Ahmann F.R., McDaniel K.M., Paquin M.L., Clark V.A., Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Research 1987, 47:281-286.
118. Nakayama M., Gonzalgo M.L., Yegnasubramanian S., Lin X., De Marzo A.M., Nelson W.G. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. Journal of Cellular Biochemistry 2004, 91:540-552.
119. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
120. Osman I., Drobnjak M., Fazzari M., Ferrara J., Scher H.I., Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clinical Cancer Research 1999, 5:2082-2088.
121. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., Reilly J.G., Chandra D., Zhou J., Claypool K., Coghlan L., Tang D.G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708.
122. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute 2006, 98:1777-1785.
123. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
124. Rajasekhar V.K., Studer L., Gerald W., Socci N.D., Scher H.I. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nature Communication 2011, 2:162.
125. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
126. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
127. Richardson G.D., Robson C.N., Lang S.H., Neal D.E., Maitland N.J., Collins A.T. CD133, a novel marker for human prostatic epithelial stem cells. Journal of Cell Science 2004, 117:3539-3545.
128. Risbridger G.P., Davis I.D., Birrell S.N., Tilley W.D. Breast and prostate cancer: more similar than different. Nature Reviews Cancer 2010, 10:205-212.
129. Robbins E.W., Travanty E.A., Yang K., Iczkowski K.A. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BMC Cancer 2008, 8:260.
130. Robinson E.J., Neal D.E., Collins A.T. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 1998, 37:149-160.
131. Roloff T.C., Nuber U.A. Chromatin, epigenetics and stem cells. European Journal of Cell Biology 2005, 84:123-135.
132. Ruijter E.T., Miller G.J., van de Kaa C.A., van Bokhoven A., Bussemakers M.J., Debruyne F.M., Ruiter D.J., Schalken J.A. Molecular analysis of multifocal prostate cancer lesions. Journal of Pathology 1999, 188:271-277.
133. Rutella S., Bonanno G., Procoli A., Mariotti A., Corallo M., Prisco M.G., Eramo A., Napoletano C., Gallo D., Perillo A., Nuti M., Pierelli L., Testa U., Scambia G., Ferrandina G. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clinical Cancer Research 2009, 15:4299-4311.
134. Sabbath K.D., Griffin J.D. Clonogenic cells in acute myeloblastic leukaemia. Scand Journal of Haematology 1985, 35:251-256.
135. Sadi M.V., Barrack E.R. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer. 1993, 71:2574-2580.
136. Sanchez P., Hernandez A.M., Stecca B., Kahler A.J., DeGueme A.M., Barrett A., Beyna M., Datta M.W., Datta S., Ruiz i Altaba A. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:12561-12566.
137. Schmelz M., Moll R., Hesse U., Prasad A.R., Gandolfi J.A., Hasan S.R., Bartholdi M., Cress A.E. Identification of a stem cell candidate in the normal human prostate gland. European Journal of Cell Biology 2005, 84:341-354.
138. Sen G.L., Reuter J.A., Webster D.E., Zhu L., Khavari P.A. DNMT1 maintains progenitor function in self-renewing somatic tissue. Nature 2010, 463:563-567.
139. Setlur S.R., Mertz K.D., Hoshida Y., Demichelis F., Lupien M., Perner S., Sboner A., Pawitan Y., Andren O., Johnson L.A., Tang J., Adami H.O., Calza S., Chinnaiyan A.M., Rhodes D., Tomlins S., Fall K., Mucci L.A., Kantoff P.W., Stampfer M.J., Andersson S.O., Varenhorst E., Johansson J.E., Brown M., Golub T.R., Rubin M.A. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. Journal of the National Cancer Institute 2008, 100:815-825.
140. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes and Development 2010, 24:1967-2000.
141. Sherwood E.R., Theyer G., Steiner G., Berg L.A., Kozlowski J.M., Lee C. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate. Prostate 1991, 18:303-314.
142. Signoretti S., Waltregny D., Dilks J., Isaac B., Lin D., Garraway L., Yang A., Montironi R., McKeon F., Loda M. P63 is a prostate basal cell marker and is required for prostate development. American Journal of Pathology 2000, 157:1769-1775.
143. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Research 2003, 63:5821-5828.
144. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour-initiating cells. Nature 2004, 432:396-401.
145. Sontag E., Fedorov S., Kamibayashi C., Robbins D., Cobb M., Mumby M. The interaction of SV-40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993, 75:887-897.
146. Sugimura Y., Cunha G.R., Donjacour A.A. Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biology of Reproduction 1986, 34:973-983.
147. Sun S., Sprenger C.C., Vessella R.L., Haugk K., Soriano K., Mostaghel E.A., Page S.T., Coleman I.M., Nguyen H.M., Sun H., Nelson P.S., Plymate S.R. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Journal of Clinical Investigation 2010, 120:2715-2730.
148. Tang D.G., Patrawala L., Calhoun T., Bhatia B., Choy G., Schneider-Broussard R., Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Molecular Carcinogenesis 2007, 46:1-14.
149. Taplin M.E., Rajeshkumar B., Halabi S., Werner C.P., Woda B.A., Picus J., Stadler W., Hayes D.F., Kantoff P.W., Vogelzang N.J., Small E.J. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Journal of Clinical Oncology 2003, 21:2673-2678.
150. Thomson A.A. Role of androgens and fibroblast growth factors in prostatic development. Reproduction 2001, 121:187-195.
151. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
152. Tsujimura A., Koikawa Y., Salm S., Takao T., Coetzee S., Moscatelli D., Shapiro E., Lepor H., Sun T.T., Wilson E.L. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. Journal of Cell Biology 2002, 157:1257-1265.
153. van den Hoogen C., van der Horst G., Cheung H., Buijs J.T., Lippitt J.M., Guzman-Ramirez N., Hamdy F.C., Eaton C.L., Thalmann G.N., Cecchini M.G., Pelger R.C., van der Pluijm G. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Research 2010, 70:5163-5173.
154. van Leenders G.J., Aalders T.W., Hulsbergen-van de Kaa C.A., Ruiter D.J., Schalken J.A. Expression of basal cell keratins in human prostate cancer metastases and cell lines. Journal of Pathology 2001, 195:563-570.
155. van Leenders G.J., Gage W.R., Hicks J.L., van Balken B., Aalders T.W., Schalken J.A., De Marzo A.M. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. American Journal of Pathology 2003, 162:1529-1537.
156. van Leenders, G.J. and Schalken, J.A., 2001. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis, BJU Int. 88 Suppl 2, 35-42; discussion 49-50.
157. Vander Griend D.J., Karthaus W.L., Dalrymple S., Meeker A., DeMarzo A.M., Isaacs J.T. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Research 2008, 68:9703-9711.
158. Verhagen A.P., Aalders T.W., Ramaekers F.C., Debruyne F.M., Schalken J.A. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate 1988, 13:25-38.
159. Verhagen A.P., Ramaekers F.C., Aalders T.W., Schaafsma H.E., Debruyne F.M., Schalken J.A. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Research 1992, 52:6182-6187.
160. Verras M., Brown J., Li X., Nusse R., Sun Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Research 2004, 64:8860-8866.
161. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
162. Wang S., Garcia A.J., Wu M., Lawson D.A., Witte O.N., Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:1480-1485.
163. Wang X., Kruithof-de Julio M., Economides K.D., Walker D., Yu H., Halili M.V., Hu Y.P., Price S.M., Abate-Shen C., Shen M.M. A luminal epithelial stem cell that is a cell-of-origin for prostate cancer. Nature 2009, 461:495-500.
164. Wang, Z.A. and Shen, M.M., 2010. Revisiting the concept of cancer stem cells in prostate cancer, Oncogene.
165. Wikstrom P., Bergh A., Damber J.E. Transforming growth factor-beta1 and prostate cancer. Scandinavian Journal of Urology and Nephrology 2000, 34:85-94.
166. Williams R.T., den Besten W., Sherr C.J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes and Development 2007, 21:2283-2287.
167. Winquist R.J., Boucher D.M., Wood M., Furey B.F. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine. Biochemical Pharmacology 2009, 78:326-334.
168. Xin L., Lawson D.A., Witte O.N. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:6942-6947.
169. Xue Y., Smedts F., Debruyne F.M., de la Rosette J.J., Schalken J.A. Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate 1998, 34:292-301.
170. Yu, C., Yao, Z., Dai, J., Zhang, X., Escara-Wilke, J. and Keller, E., 2007. Aldehyde dehydrogenase is a marker of prostate cancer stem cell-like cells in cell lines[abstract 1300]. In: American Association for Cancer Research Annual Meeting: Proceedings: Los Angeles, CA.
171. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine 2001, 7:1028-1034.